Johnson & Johnson is ordered to pay $572 million for its role in Oklahoma's opioid epidemic; President Trump eliminates protection of sick immigrants to remain in the United States; a federal judge is expected to rule on the Missouri law banning abortion after 8 weeks today.
Johnson & Johnson has been ordered by an Oklahoma judge to pay $572 million in restitution for their role in the state’s opioid crisis, according to Kaiser Health News. Oklahoma had originally sued for $17 billion as they attributed responsibility to the drugmaker for deceptive marketing practices that resulted in the deaths of 6000 citizens. Judge Thad Balkman cited that “the opioid crisis is an imminent danger and menace to Oklahomans,” in delivering his decision Monday. Johnson & Johnson released a statement announcing their plans to appeal the decision.
The Trump administration issued letters to families this month announcing their elimination of a protection for immigrants to remain in the country and avoid deportation while they or their relatives receive life-saving medical treatments. The Associated Press reports that the policy change became effective on August 7 and affects all pending requests, including from immigrants seeking a renewal of their 2-year authorization and first-time applicants. This move adds to the aggressive stance Trump has taken on immigrants as the administration wants to deny green cards to immigrants who use Medicaid, food stamps, and other types of public assistance.
A federal judge announced he will rule today on whether Missouri’s new abortion law banning abortions at or after 8 weeks of pregnancy will go into scheduled effect this week, reported by The Associated Press. US District Judge Howard Sachs will issue his decision after hearing arguments by Planned Parenthood and the American Civil Liberties Union on Monday. The law, which would additionally ban abortions based solely on race, sex, or a diagnosis, is scheduled to become effective Wednesday barring Sachs’ ruling.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More